Traws Pharma (NASDAQ:TRAW) Trading Down 2.7% – Time to Sell?

Traws Pharma, Inc. (NASDAQ:TRAW) was down 2.7% during trading on Wednesday . The company traded as low as $2.51 and last traded at $2.56. Approximately 69,859 shares were traded during mid-day trading, a decline of 85% from the average daily volume of 457,729 shares. The stock had previously closed at $2.63.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on TRAW shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Traws Pharma in a report on Wednesday, November 19th. Wall Street Zen upgraded shares of Traws Pharma to a “hold” rating in a report on Saturday, November 1st. One analyst has rated the stock with a Sell rating, According to MarketBeat, Traws Pharma presently has an average rating of “Sell”.

Traws Pharma Trading Down 2.7%

The company has a 50 day simple moving average of $2.34 and a 200 day simple moving average of $1.82. The stock has a market capitalization of $20.46 million, a PE ratio of 0.03 and a beta of 1.73.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, November 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.16) by $8.82. Traws Pharma had a negative return on equity of 1,812.48% and a net margin of 3,028.25%.

Hedge Funds Weigh In On Traws Pharma

Several hedge funds have recently added to or reduced their stakes in TRAW. Adage Capital Partners GP L.L.C. acquired a new position in Traws Pharma during the first quarter worth about $759,000. Vestal Point Capital LP grew its position in shares of Traws Pharma by 133.3% in the first quarter. Vestal Point Capital LP now owns 175,000 shares of the company’s stock valued at $402,000 after purchasing an additional 100,000 shares during the last quarter. Finally, Two Sigma Investments LP increased its stake in shares of Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock worth $41,000 after purchasing an additional 5,955 shares in the last quarter. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.